Featured Publications

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine
December 2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope
May 2023

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Other Development Candidates

Title	Disease Target	Product
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight — April 2019	HER2
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape Molecular Therapy - Oncolytics — March 2023	Glioblastoma Multiforme	EGFRvIII-DBTE
Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo Frontiers in Immunology — February 2023	Melanoma	Antibody-cytokine chimera TA99-HL2-KOA1 with DLnano-vaccine

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases